WuXi XDC Achieves Best CDMO Recognition for Second Year
WuXi XDC Cayman Inc. ('WuXi XDC' or 'the Company', stock code: 2268.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has been honored with the 'Best CDMO' award at the World ADC Awards 2024. This accomplishment marks the second consecutive year the company has received this prestigious recognition, affirming its position as a leader in the production and development of antibody-drug conjugates (ADCs). Notably, this follows their previous accolades, winning 'Best CDMO' in 2023 and being a runner-up in 2022 for 'Best CMO'. The company was also shortlisted this year for 'Best ADC Platform Technology' and 'Best CRO', showcasing its exceptional research and development capabilities.
Acknowledging Excellence in ADC Development
Presented at the annual World ADC conference, this award celebrates WuXi XDC's commitment to providing superior end-to-end CRDMO services. The recognition has highlighted WuXi XDC's technical strengths and innovation in meeting the intricate needs of clients in the global ADC market. By continuously improving services, WuXi XDC demonstrates dedication to excellence in the bioconjugate sector.
Significance of the World ADC Awards
The World ADC Awards serve as a significant annual event to recognize outstanding achievements in antibody-drug conjugate development. Bringing together key players in the industry, this event highlights advancements in ADC technology and the importance of collaboration in this rapidly evolving field. During the 2024 gatherings, experts discussed developments in ADCs and XDCs, facilitating partnerships and creating connections that drive innovation.
Leadership in Innovation
Dr. Jimmy Li, the CEO of WuXi XDC, expressed pride in the company's accomplishments and the continuous recognition received at the World ADC Awards. He stated, 'Winning the prestigious award signifies our team's unwavering commitment to innovation. It reflects the trust our clients have in us, and receiving the 'Best CDMO' award for two years in a row showcases our consistent efforts and reputation as a global leader in the ADC industry.' His comments underline the company’s mission to enhance the discovery and manufacturing processes through a comprehensive open-access platform, ultimately benefiting patients worldwide.
Advancements in ADC Development Processes
WuXi XDC's integrated CRDMO platform significantly enhances the production timeline and reduces risks associated with ADC development. The company has streamlined the DNA-to-IND process to an impressive 15 months, cutting the traditional timeline for entering clinical trials almost in half. Furthermore, WuXi XDC accelerates the development to Biologics License Application (BLA) within 24-36 months, showcasing remarkable efficiency in its operations.
A Reliable Partner in Bioconjugate Development
The company's success is rooted in its extensive experience and deep expertise in ADC technology and bioconjugate handling. By harmonizing discovery, development, and manufacturing, WuXi XDC ensures effective collaboration that minimizes risks and enhances productivity throughout the ADC development journey. Their all-in-one manufacturing strategy encompasses all key phases of ADC production, ensuring high-quality results.
Building a Global Client Network
In the 2024 interim report, it was noted that WuXi XDC has expanded its client base to 419 global partners. Impressively, 13 out of the top 20 pharmaceutical companies worldwide have partnered with WuXi XDC, demonstrating the trust and esteem held in the company’s capabilities. This growing clientele reflects WuXi XDC's ongoing commitment to providing high-quality service in the competitive landscape of ADC development.
Driving Continuous Improvement in Healthcare Solutions
WuXi XDC's ongoing recognition at events such as the World ADC Awards enhances its commitment to innovation, empowering clients to accelerate the creation of groundbreaking therapies. As a key CRDMO in ADC and bioconjugates, WuXi XDC is dedicated to remaining at the forefront of advancements in this vital field, always aiming to benefit patients around the globe.
About WuXi XDC
WuXi XDC Cayman Inc. specializes in the CRDMO sector, focusing on both antibody-drug conjugates (ADCs) and the broader bioconjugate market. The company provides comprehensive contract research, development, and manufacturing services designed to assist organizations across the globe. With a commitment to innovation and excellence, WuXi XDC stands out by offering integrated solutions that meet the complex demands of the bioconjugate industry.
Frequently Asked Questions
What is the World ADC Awards?
The World ADC Awards recognize outstanding achievements in the field of antibody-drug conjugate development and bring together industry leaders to foster innovation.
How has WuXi XDC been recognized in the past?
WuXi XDC has consistently received awards at the World ADC, including 'Best CDMO' in 2023 and recognition as 'Best CMO Runner-up' in 2022.
What does WuXi XDC's CRDMO platform offer?
The platform provides comprehensive end-to-end services designed to streamline the development and manufacturing of ADCs, significantly enhancing efficiency.
How does WuXi XDC ensure product quality?
WuXi XDC integrates all phases of ADC production into a single site, which promotes seamless interaction and high product quality.
Who are WuXi XDC's clients?
WuXi XDC serves a wide range of clients, including 13 of the top 20 global pharmaceutical companies, reflecting its strong market presence and reputation.
